Systematic comparison of fluorescence imaging in the near-infrared and shortwave-infrared spectral range using clinical tumor samples containing cetuximab-IRDye800CW
SWIR imaging using the targeted tracer cetuximab-IRDye800CW currently does not provide additional benefit over NIR imaging in <i>ex vivo</i> clinical samples. Background fluorescence in the SWIR region, resulting in a higher background signal, limits SWIR imaging in HNSCC samples. However, SWIR shows potential in increasing the contrast of tumor borders in PSCC samples, as shown by a higher aCNR over a line.
Authors
- Marius C. van den Heuvel (ORCID: https://orcid.org/0000-0001-6985-7107)
- Igle J. de Jong (ORCID: https://orcid.org/0000-0002-3444-5548)
- Thomas S. Nijboer (ORCID: https://orcid.org/0000-0003-0642-451X)
- Schelto Kruijff (ORCID: https://orcid.org/0000-0002-5151-7320)
- Gooitzen M. van Dam (ORCID: https://orcid.org/0000-0002-7248-8696)
- Dimitris Gorpas (ORCID: https://orcid.org/0000-0001-9576-8087)
- Wesley R. Browne (ORCID: https://orcid.org/0000-0001-5063-6961)
- Bas Keizers (ORCID: https://orcid.org/0000-0003-3798-7702)
- Floris J. Voskuil (ORCID: https://orcid.org/0000-0003-3740-4554)
- Max J. H. Witjes (ORCID: https://orcid.org/0000-0002-4135-3246)
- P. J. van der Zaag (ORCID: https://orcid.org/0000-0001-9080-4907)
- Christa A. M. van der Fels (ORCID: https://orcid.org/0000-0003-2221-0570)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Helmholtz Zentrum München (DE)
- Institute of Biological and Medical Imaging
Publication Details
- Journal
- Journal of Biomedical Optics
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1117/1.jbo.30.s1.s13708
- Citations
- 3
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.55